CXADR 靶点蛋白|抗体药物|临床药物信息

CXADR信息

英文名称：Calcium sensing receptor
中文名称：钙敏感受体
靶点别称：Parathyroid cell calcium-sensing receptor 1，FHH，FIH，HHC，Receptors， Calcium-Sensing，Extracellular calcium-sensing receptor，hCasR，GPRC2A，Calcium Sensing Receptor，Parathyroid Ca(2+)-Sensing Receptor 1，Severe Neonatal Hyperparathyroidism，Calcium-Sensing Receptor，HYPOC1，NSHPT，PCaR1，EIG8，HHC1，CaSR，CAR，Hypocalciuric Hypercalcemia 1

上市药物数量：6
临床药物数量：4
最高研发阶段：批准上市

CXADR产品列表

筛选结果

产品库

在线 (1)

物种

Human (1)

标签

His Tag (1)

属性

Protein (1)

标记

Unconjugated (1)

货号	物种	产品描述	蛋白结构	纯度	活性
CXR-H5222	Human	Human CXADR / CAR Protein, His Tag

CXADR 分子别名

CXADR,CAR,CAR4/6,HCAR

CXADR 分子背景

Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human CXADR protein contains a signal sequence, a extracellular domain (ECD) with a V type (D1) and a C2 type (D2) Iglike domain, a transmembrane segment and a intracellular domain. D1 is thought to be responsible for homodimer formation in trans within tight junctions, and is necessary and sufficient for adenovirus binding. Variants of CXADR are attached to the cell membrane by a GPI- anchor.

CXADR 前沿进展

CXADR上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Evocalcet	伊万卡塞	KHK-7580; MT-4580	批准上市	Mitsubishi Tanabe Pharma Corp	Orkedia	Japan	继发性甲状旁腺功能亢进症	Kyowa Hakko Kirin Co Ltd	2018-03-23	继发性甲状旁腺功能亢进症, 甲状旁腺癌, 原发性甲状旁腺功能亢进症, 甲状旁腺功能亢进症	详情
Etelcalcetide Hydrochloride	盐酸依特卡肽	KAI-4169; AMG-416; KAI-4169-HCl; ONO-5163	批准上市	安进	Parsabiv	United States	继发性甲状旁腺功能亢进症	Kai Pharmaceuticals Inc	2016-11-11	继发性甲状旁腺功能亢进症, 心源性水肿, 慢性肾功能不全, 终末期肾脏病	详情
Upacicalcet		SK-1403; AJT-240	批准上市	日本味之素株式会社	ウパシタ, Upasita	Japan	继发性甲状旁腺功能亢进症	Sanwa Kagaku Kenkyusho Co Ltd	2021-06-23	继发性甲状旁腺功能亢进症	详情
Strontium Ranelate	雷奈酸锶	FK-481; S-12911; S-12911-2	批准上市	Laboratoires Servier	欧思美, Osseor, Protos, Protelos	Mainland China	绝经期后骨质疏松	Les Laboratoires Servier	2004-09-20	绝经期后骨质疏松	详情
Cinacalcet Hydrochloride	盐酸西那卡塞	KRN-1493; SSS-12; AMG-073.HCl; NPS-1493; AMG-073	批准上市	安进	Parareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/Mimpara	Mainland China	继发性甲状旁腺功能亢进症, 甲状旁腺功能亢进症, 高钙血症	Kyowa Hakko Kirin Co Ltd	2004-03-08	继发性甲状旁腺功能亢进症, 肾脏移植排斥, 低磷血症, 肾病, 甲状旁腺癌, 心源性水肿, 高钙血症, 肾脏疾病, 原发性甲状旁腺功能亢进症, 前列腺癌, 骨软化症, 慢性肾功能不全, 甲状旁腺功能亢进症, 终末期肾脏病, 肾性骨营养不良	详情
Parathyroid hormone (Shire)	甲状旁腺素（Shire）	NPSP-795; rhPTH (1-84); rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558; SHP-635; SHP-634; ALX-111; 423562; EBP-05; EB-612	批准上市	Shire	Natpara, Preotact, Natpar	EU	甲状旁腺功能减退症	Takeda Pharmaceuticals International AG Ireland Branch	2006-04-24	骨质疏松症, 内分泌性骨疾病, 绝经期后骨质疏松, 低钙血症, 银屑病, 甲状旁腺功能减退症, 甲状旁腺功能亢进症	详情

CXADR临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
LNP-1892	LNP-1892	临床二期	鲁宾有限公司	甲状旁腺功能亢进症	详情
Encaleret sulfate	MK-5442; JTT-305; CLTX-305	临床三期	日本烟草（香港）有限公司	骨质疏松症, 低钙血症, 绝经期后骨质疏松, 甲状旁腺功能减退症	详情
RT-102(Rani)	RT-102	临床一期	Rani Therapeutics Holdings Inc	骨质疏松症	详情
DS-9194b	DS-9194b	临床一期	第一三共株式会社	骨质疏松症	详情

会议日历

会议一览

CXADR